Leroi Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 01-07-2024
- Paid Up Capital ₹ 1.50 Cr
as on 01-07-2024
- Company Age 19 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.12 Cr
as on 01-07-2024
- Satisfied Charges ₹ 2.26 M
as on 01-07-2024
- Revenue 44.78%
(FY 2023)
- Profit -150.76%
(FY 2023)
- Ebitda 7.47%
(FY 2023)
- Net Worth -2.27%
(FY 2023)
- Total Assets 25.91%
(FY 2023)
About Leroi Pharmaceuticals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 1.50 Cr.
The company currently has active open charges totaling ₹3.12 Cr. The company has closed loans amounting to ₹2.26 M, as per Ministry of Corporate Affairs (MCA) records.
Sanyam Arora and Annu Arora serve as directors at the Company.
- CIN/LLPIN
U24232UP2005PTC030224
- Company No.
030224
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Jun 2005
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- LocationMuzaffarnagr, Uttar Pradesh
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Leroi Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanyam Arora  | Whole-Time Director | 20-Dec-2018 | Current |
| Annu Arora | Whole-Time Director | 20-Dec-2018 | Current |
Financial Performance of Leroi Pharmaceuticals.
Leroi Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 44.78% increase. The company also saw a substantial fall in profitability, with a 150.76% decrease in profit. The company's net worth dipped by a decrease of 2.27%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Leroi Pharmaceuticals?
In 2023, Leroi Pharmaceuticals had a public holding of 34.56%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 15 Dec 2023 | ₹3.40 M | Open |
Others Creation Date: 15 Dec 2023 | ₹1.60 Cr | Open |
Others Creation Date: 16 Feb 2021 | ₹1.50 M | Open |
How Many Employees Work at Leroi Pharmaceuticals?
Leroi Pharmaceuticals has a workforce of 19 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Leroi Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Leroi Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
